Off-the-shelf CAR-T cell therapies CAR-T cell therapies have shown great promise in treating blood cancers and autoimmune diseases. Our CAR-T cell therapies are armored for potentially improved activity against diseases and are designed to reach a broad number of patients with off-the-shelf trea...
Exploring universal CAR-T19 cells (U-CAR-T19) through gene-edited methods (TALEN or CRISPR/Cas9) is strategy to resolve the limitation of autologous CAR-T19 cells in clinic, such as failure, time-consuming, and expansive cost of CAR-T cell preparation. However, (TRAC−/CD52−) U-CA...
Allogeneic CAR T cells for autoimmune diseases: a glimpse into the futuredoi:10.1038/s41392-024-01998-8Dimitrios Mougiakakoshttps://ror.org/00ggpsq73grid.5807.a0000 0001 1018 4307Department of Hematology, Oncology, and Cell TherapyOtto-von-Guericke University Magdeburg Magdeburg Germany...
The allogeneic BCMA-targeted CAR T-cell therapy P-BCMA-ALLO1 led to high response rates in heavily pretreated patients with relapsed/refractory multiple myeloma. Patients given the regimen were also able to skip invasive apheresis, bridging therapy, and manufacturing delays, per data from...
Allogeneic anti-CD19 CAR-T (Tianjin First Center Hospital): 一种CD19抑制剂药物,由Tianjin First Center Hospital (天津市第一中心医院)公司最早进行研发,目前全球最高研发状态为临床1期,作用机制: CD19抑制剂(B淋巴细胞抗原CD19抑制剂),治疗领域: 免疫系统疾病,血
Eidell, K.P., Hemann, M.T.FAS-less allogeneic CAR T cells.Nat. Biomed. Eng8, 1518–1520 (2024). https://doi.org/10.1038/s41551-024-01319-y Download citation Published20 December 2024 Issue DateDecember 2024 DOIhttps://doi.org/10.1038/s41551-024-01319-y ...
Following the publication of the first preclinical studies of allogeneic CAR-T cell cancer therapies about five years ago, an appealing narrative began to take hold – this “off-the-shelf” CAR-T would inevitably replace the pioneering autologous CAR-Ts. By 2020, numerous major companies and st...
Eidell, K.P., Hemann, M.T. FAS-less allogeneic CAR T cells. Nat. Biomed. Eng 8, 1518–1520 (2024). https://doi.org/10.1038/s41551-024-01319-y Download citation Published20 December 2024 Issue DateDecember 2024 DOIhttps://doi.org/10.1038/s41551-024-01319-y Springer Nature Limited ...
(NASDAQ: CLLS – Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells (“UCART”) in the field of immuno-oncology, and Sanofi (Euronext: SAN ...
TAICHUNG, Feb. 5, 2025 /PRNewswire/ -- China Medical University and Healthcare System Pioneers AI-Driven Drug Discovery and Allogeneic CAR-T Therapy: A Groundbreaking Leap in Cancer Treatment